Your session is about to expire
← Back to Search
Lenalidomide + Melphalan for Multiple Myeloma
Study Summary
This trial is testing the addition of lenalidomide to standard treatment for multiple myeloma to see if it improves response rates and duration of response.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My organ and bone marrow functions are normal.I have enough CD34+ stem cells collected for a transplant.I have not had a blood clot in the last 60 days.My multiple myeloma has come back or did not respond to initial treatment.I am 18 years old or older.I am able to become pregnant and will use two forms of birth control or abstain from sex.I agree to use a latex condom during sex with a female capable of becoming pregnant.I can take low-dose aspirin daily without any issues.I haven't had myeloma treatment in the last 14 days and have recovered from any previous treatment side effects.I am positive for HIV or hepatitis B/C.I do not have any uncontrolled illnesses that could affect my participation.I have undergone at least one treatment for my condition.I can take care of myself but might not be able to do heavy physical work.I am willing to take blood thinner medication as required.
- Group 1: all patients
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What conditions is melphalan commonly used to address?
"Melphalan has been prescribed to alleviate the symptoms of a variety of diseases, such as amyloidosis, muscular dystrophy, and those requiring hematopoietic stem cell transplantation. It is usually recommended after two prior systemic chemotherapy regimens have proven unsuccessful."
Is this research endeavor actively seeking participants?
"This medical experiment is no longer open to recruitment. The trial was posted on August 1st 2010 and its last update was April 12th 2022. At the moment, 807 studies with multiple myeloma as their focus are recruiting patients while 369 trials focusing on melphalan are actively seeking participants."
How many individuals are currently involved in this clinical experiment?
"No longer actively seeking participants, this trial was initially listed on August 1st 2010 and most recently updated April 12th 2022. For those looking into other studies, 807 trials that treat multiple myeloma are currently recruiting while 369 clinical experiments related to melphalan search for patients."
Share this study with friends
Copy Link
Messenger